Product
Tucatinib plus Trastuzumab Subcutaneous
1 clinical trial
4 indications
Indication
lymphomaIndication
Non-HodgkinIndication
Multiple MyelomaIndication
CancerClinical trial
Targeted Agent and Profiling Utilization Registry (TAPUR) StudyStatus: Recruiting, Estimated PCD: 2024-12-31